New treatments for malaria prevention and management
Official title: Next Generation ELQs for Treatment and Once-Monthly Protection Against Malaria
Funded at Oregon Health & Science University · NIH-11050168 · Data updated 2026-11-12
This study is working on new malaria medications that not only treat the infection quickly but also help protect people from getting malaria in the future, especially in areas where the disease is common.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oregon Health & Science University NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project start | May 1, 2025 |
| Project end | April 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $587,318 |
| NIH project number | 1R01AI182513-01A1 |
| Project ID | NIH-11050168 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals living in or traveling to malaria-endemic regions who are at risk of infection.
✕Less likely to help
Patients who are not at risk of malaria infection or those living in malaria-free regions may not benefit from this research.
What this research studies
This research focuses on developing next-generation anti-malarial drugs that provide both immediate treatment and long-term protection against malaria. The approach involves creating new medications that can act quickly to eliminate the malaria parasite and also offer sustained protection for individuals at risk of malaria infection. By targeting specific stages of the parasite's lifecycle, these drugs aim to prevent outbreaks and reduce the transmission of malaria in high-risk areas. The research will utilize advanced drug formulations to enhance effectiveness and bioavailability.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments and preventive measures against malaria, significantly reducing the disease's impact on vulnerable populations.
How similar studies have gone: Previous research has shown promise in developing new anti-malarial agents, indicating that innovative approaches in this field can lead to successful outcomes.
Where this research is happening
-
Oregon Health & Science University
Portland, United States Active
Researchers
- Principal investigator: Riscoe, Michael Kevin — Oregon Health & Science University
- Study coordinator: Riscoe, Michael Kevin
Related research
Other NIH-funded projects on the same topics.
-
Digital malaria surveillance in Ethiopia to improve outbreak detection
A collaboration to add a malaria-specific digital module to an existing surveillance system in Africa to help detect and respond to outbreaks faster.
-
Cross-sector partnership uses digital malaria surveillance in Ethiopia
A US-based team will adapt and test a digital malaria surveillance module in SORMAS to help detect and respond to malaria outbreaks in Ethiopia.
-
Malaria control project in Western Kenya to reduce illness and deaths
A large, multi-year effort in western Kenya will help track malaria spread and test ways to prevent transmission so fewer people get sick or die.
-
Optimizing tafenoquine dose to prevent relapse of vivax malaria in Asia
A study tests the best tafenoquine dose to prevent P. vivax malaria relapse in people in East Asia and Oceania.
-
Optimizing tafenoquine dose to prevent P. vivax malaria relapses in Asia
A study to find the best single-dose tafenoquine amount to prevent relapse of P. vivax malaria in people in East Asia and Oceania.
-
Severe malaria and brain risk in children
This grant studies how severe malaria in young children can affect brain development and long-term thinking and behavior, with a focus on kids in Uganda.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.